---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016473"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2023-10-17T23:59:59+00:00"
generated_at: "2026-06-09T22:43:11.485202+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Olema appoints Scott Garland to Board; brings commercial expertise for late-stage palazestrant development

## Summary
- Scott Garland appointed to Board as Class III director effective Oct 16, 2023; term through 2026 annual meeting.
- Received initial equity: options for 21,520 shares (3-year vest) and 14,347 shares (vests by 2024 annual meeting).
- Annual cash retainer $40,000 plus $6,000 for Compensation Committee service; standard indemnification agreement.
- Garland formerly CEO of Portola (led Andexxa launch and Alexion acquisition) and held senior roles at Exelixis, Genentech, Amgen.
- Company highlights his commercial leadership as palazestrant advances to Phase 3 for breast cancer.

## SEC filing metadata
- accession: 0001558370-23-016473
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2023-10-17T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000155837023016473/0001558370-23-016473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000155837023016473/olma-20231013x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016473
- JSON: https://secwatch.observer/filing/0001558370-23-016473.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.